Bluebird Bio's (BLUE) Abecma Becomes the First BCMA Targeting CAR-T Therapy to Reach the Market - Stifel
Tweet Send to a Friend
Stifel analyst Benjamin J. Burnett reiterated a Hold rating and $31.00 price target on bluebird bio (NASDAQ: BLUE) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
